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Haemopoietic stem/progenitor cells can be mobilized into the
peripheral blood using granulocyte colony stimulating factor (G-
CSF) and granulocyte-macrophage CSF (GM-CSF), either alone
or following chemotherapy (Watts and Linch, 1997). Many
different mobilizing chemotherapy regimens have been employed,
with single-agent cyclophosphamide one of the most frequent. The
doses of cyclophosphamide used have varied between 1 g m–2 and
7g  m –2 and at our institution we have used 1.5 g m–2 (Jones et al,
1994; Watts et al, 1997b, 1998). This dose of cyclophosphamide
followed by G-CSF is an effective mobilizing regimen in that the
minimum required number of CD34+ cells could be collected 
in two aphereses in 90% of patients with previously treated
lymphoma (Watts et al, 1997b). A major advantage of this regimen
is that it can be given as an out-patient, few patients (5%) require
admission for the treatment of chemotherapy-related complica-
tions and the stem/progenitor cell mobilization kinetics are highly
predictable (Watts et al, 1995, 1997b).
There is some evidence that higher doses of cyclophosphamide
result in greater progenitor/stem cell mobilization (Rowlings et al,
1992; Goldschmidt et al, 1996; Schwartzberg et al, 1998) but the
complication rate of the procedure rises dramatically. One study
suggested that combination chemotherapy was superior to inter-
mediate dose cyclophosphamide (McQuaker et al, 1997) but
another comparing cyclophosphamide 4.5 g m–2 with a combina-
tion of cyclophosphamide and etoposide found no advantage to the
more toxic combination therapy (Ketterer et al, 1997).
Single-agent cyclophosphamide at a dose of 1.5 g m–2 is not,
however, an optimal anti-lymphoma regimen particularly in
patients who have just failed a cyclophosphamide-containing
combination chemotherapy regimen. We have therefore explored
the use of ESHAP (etoposide, ara-C, methylprednisolone and
cisplatin) as a mobilizing regimen (Watts et al, 1996) as it is a
proven lymphoma salvage regimen and contains no highly stem
cell-toxic alkylating agents which might mitigate against effective
mobilization (Velasquez et al, 1994).
We report here ESHAP/G-CSF mobilization of 84 patients with
lymphoma (Hodgkin’s disease, low-grade and high-grade non-
Hodgkin’s lymphoma (NHL)). To allow meaningful comparison
with the results obtained with cyclophosphamide 1.5 g m–2 we
have carried out matched pairs analysis with cyclophosphamide-
mobilized patients, matching for those factors that can influence
mobilization efficacy.
PATIENTS STUDIED
Eighty-four patients with lymphoma have received ESHAP
chemotherapy followed by G-CSF (as detailed below) prior to
collection of peripheral blood stem cell (PBSC) at UCLH since
October 1995. Matching was carried out using a database
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Correspondence to: DC Linchcontaining 178 lymphoma patients mobilized with cyclophos-
phamide 1.5 g m–2 between July 1992 and October 1997. The latter
patients comprised 71 with Hodgkin’s disease, 50 with low-grade
NHL and 63 with high-grade NHL. The two groups were of
similar weights, the median value being 75 kg in the ESHAP
group (range 43–126 kg) and 73.5 kg in the cyclophosphamide
group (range 47–103 kg).
Matching criteria
Successful matches were determined using criteria which we have
previously shown to influence mobilization in a cohort of
lymphoma patients at our centre (Watts et al, 1997b). These
included matching for diagnosis, receipt of previous radiotherapy
and mini-BEAM therapy. Having fulfilled these criteria the
cyclophosphamide mobilized patient was then selected on the
basis of the number of chemotherapy cycles the patient had
received with a limit of only ± 2 cycles allowed. No patient in this
series had microscopic evidence of bone marrow involvement at
the time of mobilization. All of these factors have been demon-
strated in a number of studies to affect progenitor yields (Haas et
al, 1994; Bensinger et al, 1995; Morton et al, 1997; Weaver et al,
1998).
Mobilization regimens and apheresis
The patients mobilized with low-dose cyclophosphamide (1.5 g
m–2) were given this drug intravenously (i.v.) on day 1, followed
by G-CSF given subcutaneously (s.c.) at 10 mg kg–1 (filgrastim) or
a single vial of lenograstim (263 mg) 24 h afterwards, and daily
thereafter until harvesting was complete. Apheresis commenced
on a rising WBC from the neutropenic nadir, the optimal first
harvest progenitor yields were obtained when the WBC first
exceeded 5.0 ´ 109 l–1 (Watts et al, 1995) typically on day 10 (range
8–12). In 77/78 of the cyclophosphamide group this WBC was
achieved at first harvest. In one patient the recovery WBC only
attained 3.2 ´ 109 l–1 by day 14 when apheresis commenced (Table
1). The ESHAP protocol (Velasquez et al, 1994) involved
overnight hydration followed by etoposide at 40 mg m–2 i.v. days
1–4, cisplatin at 25 mg m–2 days 1–4, cytarabine 2 g m–2 day 1 and
methyl-prednisolone 500 mg i.v. days 1–5. This was followed on
day 6 with daily G-CSF as for the cyclophosphamide-mobilized
patients until completion of harvest. The first harvest collected
with this protocol was on day 15 providing the recovery WBC
exceeded 3.0 ´ 109 l–1 (range day 15–18). The WBC kinetics of the
ESHAP mobilization protocol were established with frequent
blood counts in the early part of the study (Figure 1).
All of the final 78 clinically matched ESHAP/G-CSF mobilized
patients were harvested on a continuous apheresis machine. Sixty-
five patients were collected on a Baxter CS3000 (Baxter
Healthcare Ltd, Berkshire, UK) set to process a fixed 10 l blood
volume and the remaining 13 patients collected on a COBE
Spectra (COBE Laboratories Ltd, Gloucester, UK.) with a median
of 11.8 l processed. Sixty-six of the cyclophosphamide/G-CSF-
matched patients were also harvested on these machines, 47 on the
Baxter machine as described and 19 on the COBE machine
(median 12.2 l blood volume processed). Twelve patients in the
cyclophosphamide-mobilized group were harvested with an inter-
mittent collection device, the Haemonetics V50 (Haemonetics Ltd,
Leeds, UK) as previously described (Jones et al, 1994; Watts et al,
1997b). The progenitor yield comparison between the two mobi-
lization protocols in the present study was performed with and
without the 12 patients pairs which included intermittent apheresis
technology. One to three apheresis harvests were collected, the
number of aphereses being determined by the progenitor yields
obtained.
Progenitor cell assays
A sterile sample from each harvest was diluted 1/10 (for cell
counts) and 1/100 (for colony assays) in RPMI containing 10%
fetal calf serum and 20 U ml–1 heparin. Harvest cell counts, CD34-
positive cell numbers and granulocyte/monocyte-colony forming
cells (GM-CFC) were performed as described previously (Watts et
al, 1997b).
RESULTS
Toxicity of ESHAP regimen
In all 84 patients, ESHAP was administered as in-patient therapy
with discharge following the cisplatin infusion. Seven patients
(8%) required subsequent readmission to hospital prior to their
apheresis date, four with fevers and presumed sepsis, three of
whom had severe neutropenia (< 0.5 ´ 109 l–1) and one who was
never neutropenic. Two patients were admitted for platelet transfu-
sions (platelets < 15 ´ 109 l–1) although neither was bleeding or
septic. A further patient was admitted with chest pain for exclusion
of a pulmonary embolus. His blood counts were in the normal
range and no cause of the chest pain was ever discovered.
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Figure 1 WBC kinetics following mobilization with ESHAP and G-CSF
Table 1 Clinical factors matched between ESHAP + G-CSF and
cyclophosphamide + G-CSF mobilized patients
Diagnosis Prior Prior Prior RT and Prior cycles of
(n) RT mini-BEAM mini-BEAM chemoa
HD 26 14/26 6/26 2/26 8 (2–16)
HGNHL 41 6/41 5/26 0/26 7 (3–14)
LGNHL 11 1/11 1/11 0/11 8 (5–17)
aOne month continuous alkylating therapy counted as one cycle of
chemotherapy.Matching of ESHAP recipients to cyclophosphamide
1.5 g m–2 recipients
Seventy-eight of the 84 ESHAP recipients could be matched for
criteria likely to influence mobilization efficiency as detailed in
the Methods section. The frequency of these factors for each histo-
logical type, and the number of prior chemotherapy cycles is
detailed in Table 2. Furthermore, when the matched ESHAP
patients were compared to the cyclophosphamide recipients there
was no difference in sex, age, receipt of prior alkylating therapy
and time from last chemotherapy to mobilization chemotherapy.
The disease status of the two mobilization groups at the time of
mobilization is summarized in Table 1.
Comparison of harvest yields for matched ESHAP and
cyclophosphamide recipients
The mobilization results for the matched pairs are shown in Table
3. Data is shown for the first harvest and for the total of all
harvests collected. The number of MNC was similar with both
groups but the number of CD34+ cells and GM-CFC was signifi-
cantly greater (P < 0.001 for both). When total yields were
compared the result with ESHAP was again significantly better,
although the differences were less marked than for the first
harvest. This is because 56 (72%) of ESHAP recipients only had
one harvest (all with more than 2 ´ 106 kg–1 CD34+ cells from a
single harvest), whereas only 17 (22%) of cyclophosphamide
recipients had only one harvest. The average number of collections
was 1.4 for ESHAP recipients and 2.1 for cyclophosphamide
recipients.
Twelve of the matched cyclophosphamide recipients had been
apheresed using an intermittent flow machine, whereas all the
ESHAP recipients had been apheresed with a continuous flow
device. To ensure that the use of the intermittent flow device had
not prejudiced the results in the cyclophosphamide patients, the
comparative analysis was repeated considering only the matched
pairs who had been collected on a continuous flow machine. The
results were very similar to when all 78 pairs were considered. For
instance, the median number of CD34+ cells collected with the
first harvest was 4.1 ´ 106 kg–1 in the ESHAP recipients and 
1.9 ´ 106 kg–1 in the cyclophosphamide recipients (P = 0.006). 
The corresponding values for GM-CFC were 4.8 ´ 105 kg–1 and 
2.7 ´ 105 kg–1 respectively (P < 0.001).
In practice the median number of progenitor cells collected is
less important than the proportion of patients achieving pre-
defined threshold levels. The proportion of patients achieving the
various thresholds is shown in Table 4.
The six ESHAP recipients who could not be matched were 
all successfully mobilized, with four out of the six having over 
1 ´ 106 kg–1 CD34+ cells in the first collection the median value
being 5.7 ´ 106 kg–1. Exclusion of these patients did not therefore
significantly influence the results obtained.
Haematological recovery
Sixty-five of the cyclophosphamide mobilized patients and 60 of
the ESHAP mobilized patients are evaluable for engraftment. The
median time to engraftment was similar for both groups (12 days
and 11 days to a neutrophil count of > 0.5 ´ 109 l–1 and 11 days and
12 days to platelet independence, defined as an unsupported
platelet count above 15 ´ 109 l–1) in the cyclophosphamide and
ESHAP groups respectively. There were ten patients with slow
(>21 days) platelet recovery in the cyclophosphamide group
compared to only five in the ESHAP group but this difference was
not significant.
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Table 2 Disease status at the time of PBSC collection
Cyclophosphamide- ESHAP-
Status at mobilization mobilized patients mobilized patients
At diagnosis 1 0
PR/CR to first-line therapy 22 24
Primary refractory to first 15 11
line therapy
First relapse 23 28
Beyond first relapse 17 15a
Total 78 78
aSix patients had received prior stem cell transplants.
Table 3 Apheresis characteristics and progenitor yields obtained at first harvest and in total apheresis collections in 78
ESHAP+ G-CSF-mobilized patients compared to matched cyclophosphamide + G-CSF-mobilized patients
ESHAP Cyclophosphamide P-values
+ G-CSF + G-CSF
First harvest yields (paired t-test)
PB WBC ´ 109 l–1 9.0 (2.9–63.6) 10.0 (3.2a–51.9)
Collection day 15 (14–19) 10 (8–16)
MNC ´ 108 kg–1 2.0 (0.5–7.9) 1.9 (0.7–7.5) NS
CD34% 2.4 (<0.1–20.1) 0.9 (0.1–9.2) <0.001
CD34 ´ 106 kg–1 4.8 (<0.1–80.2) 1.7 (0.1–28.8) <0.001
GM-CFC ´ 105 kg–1 4.9 (<0.1–86.0) 2.3 (<0.1–11.8) <0.001
Total harvest yields
Number of patients who
had (1, 2, 3 or 4) (56, 15, 6, 1) (17, 37, 24, 0)
apheresis collections
performed respectively
MNC ´ 108 kg–1 2.7 (0.5–9.2) 3.7 (0.9–15.6) 0.002
CD34 ´ 106 kg–1 4.9 (<0.1–80.2) 3.3 (0.2–41.0) 0.032
GM-CFC ´ 105 kg–1 6.1 (<0.1–86.0) 4.3 (0.2–21.2) 0.008
aIn one patient the recovery WBC was particularly slow and was only 3.2 ´109/l on day 14 when apheresis commenced.ESHAP/G vs cyclo/G for PBSC mobilization 281
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DISCUSSION
A large number of regimens have been used for stem cell mobi-
lization. In some circumstances G-CSF alone is required (e.g.
normal donors) or is adequate, but the general consensus is that
improved yields are obtained with the combination of
chemotherapy and growth factors. In many situations, such as
relapsed and resistant lymphoma, the mobilizing protocol must
also have good anti-tumour activity to test tumour chemosensi-
tivity and effect bulk reduction.
Intermediate dose cyclophosphamide (1.5 g m–2) plus G-CSF
has been extensively used in our centre. It has the advantage of
being able to be given as a day case, only causes complications
requiring readmission in about 5% of cases, and is efficacious in
the large majority of patients (Watts et al, 1997b, 1998). Some
patients do fail to mobilize the required or desired number of pro-
genitor cells, however, and single-agent cyclophosphamide at this
dose is not optimal anti-lymphoma therapy. When greater anti-
lymphoma activity has been required we have used the highly
effective mini-BEAM or dexa-BEAM regimens, but their use is
limited by stem cell toxicity with a reduction in quantity and
quality of subsequent harvest yields (Dreger et al, 1995; Watts et
al, 1997b; Weaver et al, 1998). We therefore chose to explore the
value of the ESHAP regimen which is highly effective in a range
of lymphoma types, is less toxic than the DHAP regimen, the fore-
runner to ESHAP, and contains no stem cell toxic agents
(Velasquez et al, 1994). ESHAP was very well tolerated. Only
seven out of 84 patients (8%) required re-admission following the
administration of ESHAP which does not differ significantly from
the re-admission rate following cyclophosphamide 1.5 g m–2. Only
two patients required platelet transfusions and when ESHAP is
followed by G-CSF administration, as was given here for mobi-
lization, severe protracted neutropenia was infrequent (Figure 1).
In this study ESHAP was administered on an in-patient basis over
5 days, which is a clear disadvantage to the regimen. However, in
selected patients ESHAP can be given on an out-patient basis
which reduces the costs of the procedure.
ESHAP was found to be a highly effective mobilization
regimen especially when it is considered that many of the patients
in this series were heavily pretreated. The median yield of CD34+
cells with the first apheresis was 4.8 ´ 106 kg–1 and in 84% of
patients a threshold value of 2 ´ 106 kg–1 was achieved with the
first apheresis. These values are superior to our reported experi-
ence with cyclophosphamide 1.5 g m–2 but considerable care must
be exercised in interpreting such results in the absence of a suit-
able control group. Ideally, randomized controlled trials are
required but this was not possible in this situation where many
patients with poor prognosis disease were considered to require
more potent anti-lymphoma therapy than could be achieved with
intermediate dose cyclophosphamide alone. For this reason we
have performed a match pairs analysis, matching for all the vari-
ables we have previously found to influence progenitor yield,
made possible by the fact that we had previously mobilized 178
patients with the cyclophosphamide and G-CSF regimen. This
analysis confirms the superiority of ESHAP + G-CSF as a mobi-
lization regimen.
It should be noted that the higher CD34+ cell yield was
achieved with a comparable MNC harvest so that the proportion of
CD34+ cells in the harvest was highly significantly increased.
This is likely to be due to the lympholytic effect of the high-dose
steroids within the ESHAP regimen. The higher percentage of
CD34+ cells in the harvest may be advantageous if CD34+ cell
purification is being considered as we have previously shown that
low CD34+ cell percentage is associated with lower final purities
after clinical scale purification procedures (Watts et al, 1997a).
Both cohorts of patients had similar engraftment times but this
relates to the fact that minimal progenitor thresholds were applied.
It does indicate, however, that the quality of the ESHAP-mobilized
cells is satisfactory. The cyclophosphamide patients required 
more aphereses. A total of 108 collections were performed in 
the ESHAP-mobilized patients compared to 163 in the cyclophos-
phamide-mobilized patients, and this has relevance to any
cost–benefit comparison of the two mobilization regimens. Even
taking this into account, ESHAP, which was generally given as an
in-patient regimen is likely to be more expensive than cyclophos-
phamide. Its major benefit relates to the proven anti-lymphoma
activity of ESHAP (Velasquez et al, 1994) and in patients who are
in complete response at the time of mobilization and have no poor
risk factors for mobilization cyclophosphamide remains a suitable
mobilization regimen.
It is difficult to compare the ESHAP regimen with other combi-
nation chemotherapy-mobilizing regimens because of the different
patient groups included in different series. In addition highly vari-
able numbers of apheresis procedures have been performed and
the results with the first apheresis are often not reported.
Schwartzberg and colleagues compared two cyclophosphamide
plus etoposide regimens (Schwartzberg et al, 1998) and achieved
excellent CD34+ cell yields with both. The patient group
consisted, however, of newly diagnosed patients with breast
cancer who had only received prior adjuvant chemotherapy.
McQuaker and colleagues (McQuaker et al, 1997) have reported
results with the IVE (ifosphamide 9 g m–2, VP16 600 mg m–2 and
etoposide 50 mg m–2) regimen in a group of lymphoma patients
more analogous to those in this series. Good mobilization was
achieved with a median yield of 1.94 ´ 106 kg–1 CD34+ cells per
leukapheresis. This is apparently less than with ESHAP but it
should be noted that by reporting the median per apheresis rather
than for the first apheresis this will underestimate the efficiency of
the regimen. The IVE regimen is likely to be more toxic than
ESHAP (Zinzani et al, 1994) and the high dose of ifosphamide
poses a risk of encephalitis which may make out-patient adminis-
tration difficult. Whether such toxicity is acceptable will depend
Table 4 Proportion of patients who failed to achieve various CD31 cell
threshold levels* or in the total harvest collected
Moilization CD341 cell thresholds 3106/kg
group
,1 ,2 ,3.5
First ESHAP 13 (16%) 20 (26%) 47 (60%)
harvest Cyclo 24 (31%) 43 (55%) 19 (24%)
Total ESHAP 4 (5%) 12 (15%) 52 (67%)
collected Cyclo  9(12%) 23 (29%) 37 (47%)
*The minimum yield to proceed to high dose therapy in our centre is
13106/kg CD341 cells and the aim is to collect 23106/kg CD341 cells were
obtained additional aphereses were performed providing that the peripheral
blood CD341 cell count exceeded 10310/L. The ideal yield is 3.53106/kg
CD341 cells above which delayed platelet recovery is very infrequent (Watts
et al, 1998).282 MJ Watts et al
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on the response rate compared to ESHAP, the proportion of
patients proceeding to high-dose therapy and the long-term
outcome of these patients. Randomized comparative trials are now
required.
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